Selecting the right primary container for an injectable drug product is critical, with the stakes even higher when it comes to sensitive biologics. Discover how to identify relevant testing to de-risk your product development and quickly uncover root causes of product failures.
The growing use of complex drugs means the performance of primary packaging and the effectiveness of fill and finish operations are in the spotlight. Ready-to-use (RTU) containers are in demand, as they are supplied prewashed and presterilized and can be integrated directly into aseptic fill and finish lines. Find out more about the latest generation of RTU containment solutions.
The increasing use of biologic drugs, such as monoclonal antibodies and recombinant proteins, is driving an evolution in coating technologies to ensure pharmaceutical companies and patients can make the most of new therapies. Patient safety, drug efficacy, and smooth device operation are all set to benefit from the latest cross-linked coating technology.
Syringes have a vital role to play in the administration of parenteral therapies. However, a key challenge to sensitive biologic drugs is the potential presence of tungsten from the syringe-forming process. Choosing the wrong container might compromise the stability of the drug product. Learn how to avoid problems right from the start.
Drug delivery of viscous biologics poses many challenges for pharmaceutical companies. However, development of a special thin-wall needle that fulfills the growing need for managing the delivery of viscous injectable formulations within autoinjector devices can provide a better drug delivery experience overall.
Alba®️ represents a best-in-class solution to address the development of sensitive biologics, such as highly concentrated drugs prone to silicone aggression and ophthalmic drugs. Medicines are particularly sensitive to all the components of the primary packaging they are in contact with, which might impair the compatibility between drug products and the container closure system.